Search Results for :


New Publication Highlights First Prospective Performance Assessment of the DecisionDx-Melanoma Gene Expression Profile Test

Friendswood, TX – September 5, 2017 – Castle Biosciences, Inc., a provider of molecular diagnostics to improve cancer treatment decisions, today announced the publication of the first prospective assessment of prognostic performance for the DecisionDx®-Melanoma test in a multi-center population of patients with cutaneous (skin) melanoma. The gene expression profile (GEP) test uses tumor biology … Read More


Castle Biosciences’ DecisionDx-Melanoma Test Performance Demonstrated in Newly Expanded Multicenter Cohort of 782 Patients

Friendswood, TX–August 29, 2017 – Castle Biosciences, Inc., a provider of molecular diagnostics to improve cancer treatment decisions, today announced that results of the DecisionDx®-Melanoma prognostic test’s performance in a cumulative cohort of 782 patients with cutaneous melanoma were presented during the 23rd International Pigment Cell Conference (IPCC 2017) held in Denver, CO from August … Read More


New Publication Confirms Analytic Validity of Castle Biosciences’ DecisionDx-UM Test for Uveal Melanoma in its Clinical Laboratory

Friendswood, TX – August 10, 2017 – Castle Biosciences, Inc., a provider of molecular diagnostics to improve cancer treatment decisions, today announced the publication of a study confirming the robust, reproducible performance characteristics of the DecisionDx®-UM test, the standard of care prognostic tool for patients with uveal melanoma (UM), an aggressive form of eye cancer.
Read More


Castle Biosciences’ Uveal Melanoma Test Receives Positive Medicare Local Coverage Determination and Commercial Insurance Positive Coverage Policies

Friendswood, TX – July 18, 2017 – Castle Biosciences, Inc., a provider of molecular diagnostics to improve cancer treatment decisions, today announced three important milestones in improving access to DecisionDx®-UM, the standard of care prognostic tool for patients with uveal melanoma (UM), an aggressive form of eye cancer.
Palmetto GBA, the administrator of the MolDX® … Read More